27 November 2020: Clinical Research
The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma
Lijun Hu 1ABCDEF , Ze Kong 1BCDF , Qinghong Meng 1BCD , Jianlin Wang 1BCF , Mengyun Zhou 1BC , Jingping Yu 1ACEG* , Xiaodong Jiang 2ACEG*DOI: 10.12659/MSM.927221
Med Sci Monit 2020; 26:e927221
Table 3 Cox multivariate regression analysis of the prognostic factors for nonoperative esophageal squamous cell carcinoma patients.
| Overall survival | Progression-free survival | |||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| T staging | ||||
| T | 1 (Reference) | 0.006 | 1 (Reference) | 0.045 |
| T | 2.108 (1.119, 3.973) | 0.224 | 1.644 (1.001, 2.999) | 0.035 |
| T | 3.275 (1.529, 7.013) | 0.002 | 2.385 (1.147, 4.960) | 0.020 |
| Short-term efficacy | ||||
| CR | 1 (Reference) | 0.000 | 1 (Reference) | 0.000 |
| PR | 3.654 (1.256, 10.629) | 0.017 | 3.539 (1.327, 9.439) | 0.012 |
| SD | 51.519 (13.744, 193.116) | 0.000 | 31.080 (9.147, 105.598) | 0.000 |
| CR – complete remission; HR – hazards ratio; PR – partial remission; SD – stable disease. | ||||